Summary
Pfizer Inc. announced significant restructuring plans for its global research and development (R&D) operations through an 8-K filing on February 1, 2011. The company is streamlining its R&D focus to improve innovation and productivity, which includes exiting the Sandwich, U.K. site, shifting resources from Groton, Connecticut to Cambridge, Massachusetts, and outsourcing certain functions. These strategic adjustments are expected to result in substantial pre-tax exit, disposal, and impairment charges. Investors should note the significant financial impact of these restructuring efforts. Pfizer estimates total pre-tax exit and disposal charges in the range of $1.1 billion to $1.6 billion, primarily related to employee terminations and other exit costs, to be incurred in 2011 and 2012. Additionally, the company anticipates pre-tax impairment and depreciation-asset restructuring charges of $1.1 billion to $1.3 billion, mainly for fixed assets like facilities, also to be recognized in 2011 and 2012. While these charges represent a notable cost, they are aimed at enhancing long-term R&D efficiency and competitiveness.
Key Highlights
- 1Pfizer is undergoing a significant restructuring of its global R&D operations to enhance innovation and productivity.
- 2Key actions include exiting the Sandwich, U.K. R&D site and relocating certain functions.
- 3The company estimates total pre-tax exit and disposal charges of $1.1 billion to $1.6 billion, primarily for employee termination costs.
- 4An additional $1.1 billion to $1.3 billion in pre-tax impairment and depreciation-asset restructuring charges are expected, mainly related to fixed assets.
- 5Most of these charges are anticipated to be incurred during 2011, with the remainder in 2012.
- 6The restructuring is subject to customary closing requirements and regulatory approvals.
- 7Pfizer includes a cautionary statement regarding the forward-looking nature of these estimates and potential risks.